(0.33%) 5 116.76 points
(0.33%) 38 364 points
(0.38%) 15 988 points
(-0.95%) $83.05
(5.25%) $2.02
(0.32%) $2 354.60
(0.44%) $27.66
(4.12%) $960.10
(-0.27%) $0.932
(-0.48%) $10.97
(-0.58%) $0.796
(1.66%) $93.40
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 7.61%
@ $7.87
発行日: 22 3月 2024 @ 03:10
リターン: -18.93%
前回のシグナル: 3月 22 - 02:13
前回のシグナル:
リターン: -0.76 %
Live Chart Being Loaded With Signals
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally...
Stats | |
---|---|
本日の出来高 | 1.75M |
平均出来高 | 5.53M |
時価総額 | 1.48B |
EPS | $0 ( 2024-02-22 ) |
次の収益日 | ( $-0.130 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -21.27 |
ATR14 | $0.00800 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Raab Michael | Sell | 7 500 | Common Stock |
2024-04-01 | Raab Michael | Sell | 1 518 | Common Stock |
2024-03-25 | Kelliher Mike | Buy | 205 000 | Stock Option (Right to Buy) |
2024-03-25 | Kelliher Mike | Buy | 160 000 | Common Stock |
2024-03-25 | Kelliher Mike | Buy | 0 |
INSIDER POWER |
---|
66.46 |
Last 99 transactions |
Buy: 4 000 095 | Sell: 852 364 |
ボリューム 相関
Ardelyx Inc 相関
10 最も負の相関 | |
---|---|
CSSEP | -0.96 |
EQBK | -0.957 |
FCBC | -0.951 |
MBOT | -0.949 |
DRUG | -0.945 |
BMRA | -0.944 |
EVLO | -0.942 |
FSFG | -0.942 |
SPFI | -0.941 |
BWB | -0.94 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Ardelyx Inc 相関 - 通貨/商品
Ardelyx Inc 財務諸表
Annual | 2023 |
収益: | $124.46M |
総利益: | $106.66M (85.70 %) |
EPS: | $-0.300 |
FY | 2023 |
収益: | $124.46M |
総利益: | $106.66M (85.70 %) |
EPS: | $-0.300 |
FY | 2022 |
収益: | $52.16M |
総利益: | $48.04M (92.11 %) |
EPS: | $-0.420 |
FY | 2021 |
収益: | $10.10M |
総利益: | $9.10M (90.10 %) |
EPS: | $-1.520 |
Financial Reports:
No articles found.
Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。